Publications

Romero R, Chu T*, González Robles TJ*, Smith P*, Xie Y, Kaur H, Yoder S, Zhao H, Mao C, Kang W, Pulina MV, Lawrence KE, Gopalan A, Zaidi S, Yoo K, Choi J, Fan N, Gerstner O, Karthaus WR, DeStanchina E, Ruggles KV, Westcott PMK, Chaligné R, Pe’er D, Sawyers CL. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nature Cancer. (2024). http://doi.org/10.1038/s43018-024-00838-6 PMID: 39394434

Naranjo S, Cabana CM, LaFave LM, Romero R, Shanahan SL, Bhutkar A, Westcott PMK, Schenkel JM, Ghosh A, Liao LZ, Del Priore I, Yang D, Jacks T. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes and Development, 36: 936-949. (2022). http://doi.org/10.1101/gad.349659.122 PMID: 36175034

Patel RS*, Romero R*, Watson EV, Liang AC, Burger M, Westcott PMK, Mercer KL, Bronson RT, Wooten EC, Bhutkar A, Jacks T, Elledge SJ. A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nature Communications, 13:256. (2022). http://doi.org/10.1038/s41467-021-27731-5 PMID: 35017504

Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Agudelo Rivera A, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL. Rapid interrogation of cancer cell of origin through CRISPR editing. PNAS, 118 (32) e2110344118. (2021). http://doi.org/10.1073/pnas.211034118 PMID: 34353917

Romero R*, Sánchez-Rivera FJ*, Westcott PMK, Mercer KL, Bhutkar A, Muir A, González Robles TJ, Lamboy Rodríguez S, Liao LZ, Ng SR, Li L, Colón CI, Naranjo S, Beytagh MC, Lewis CA, Hsu PP, Bronson RT, Vander Heiden MG, Jacks T. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer, 1:589–602. (2022) http://doi.org/10.1038/s43018-020-0070-1 PMID: 34414377

Li L*, Ng SR*, Colón CI, Drapkin BJ, Hsu PP, Li Z, Nabel CS, Lewis CA, Romero R, Mercer KL, Bhutkar A, Phat S, Myers MT, Muzumdar MD, Westcott PMK, Beytagh MC, Farago AF, Vander Heiden MG, Dyson NJ, Jacks T. Identification of DHODH as a therapeutic target in small cell lung cancer. Science Translational Medicine, 11:eaaw7852. (2019). http://doi.org/10.1126/scitranslmed.aaw7852 PMID: 31694929

Romero R*, Volkan SI*, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis C, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt E, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine, 23:1362– 1368. (2017). http://doi.org/10.1038/nm.4407 PMID: 28967920

Sanchez-Rivera FJ*, Papagiannakopoulos T*, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature, 516:428–431. (2014). http://doi.org/10.1038/nature13906 PMID: 25337879

Rahal R*, Frick M*, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang H, Ruddy D, Kauffman A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Seller R., Cooke VG, Gascoyne RD, Lenz G, Stegmeier F. Pharmacological and genomic profiling identifies NFkB-targeted treatment strategies for mantle cell lymphoma. Nature Medicine, 20:87-92. (2014). http://doi.org/10.1038/nm.3435 PMID: 24362935

Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CWM, Stegemeier F, Jagani Z. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. U.S.A. 111, 3128–3133 (2014). http://doi.org10.1073/pnas.1316793111 PMID: 24520176